JP2017526703A5 - - Google Patents

Info

Publication number

JP2017526703A5

JP2017526703A5 JP2017513111A JP2017513111A JP2017526703A5 JP 2017526703 A5 JP2017526703 A5 JP 2017526703A5 JP 2017513111 A JP2017513111 A JP 2017513111A JP 2017513111 A JP2017513111 A JP 2017513111A JP 2017526703 A5 JP2017526703 A5 JP 2017526703A5

Authority

JP

Japan

Prior art keywords

item

infusion

dose

neurostimulatory steroid

subject

Prior art date

2015-09-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims description 248
• 238000001802 infusion Methods 0.000 claims description 112
• AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 claims description 55
• 239000000203 mixture Substances 0.000 claims description 32
• 229920000858 Cyclodextrin Polymers 0.000 claims description 25
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 24
• 201000009916 Postpartum depression Diseases 0.000 claims description 11
• AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 claims 11
• 150000003431 steroids Chemical class 0.000 description 156
• AURFZBICLPNKBZ-YZRLXODZSA-N 3alpha-hydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-YZRLXODZSA-N 0.000 description 45
• 230000001225 therapeutic effect Effects 0.000 description 35
• 208000024891 symptom Diseases 0.000 description 32
• 206010044565 Tremor Diseases 0.000 description 30
• 238000012423 maintenance Methods 0.000 description 30
• 208000019901 Anxiety disease Diseases 0.000 description 28
• 150000001875 compounds Chemical class 0.000 description 26
• 230000036470 plasma concentration Effects 0.000 description 16
• 238000002347 injection Methods 0.000 description 12
• 239000007924 injection Substances 0.000 description 12
• 201000006517 essential tremor Diseases 0.000 description 10
• 230000007423 decrease Effects 0.000 description 7
• 230000003247 decreasing effect Effects 0.000 description 7
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 5
• 206010039897 Sedation Diseases 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 238000002360 preparation method Methods 0.000 description 4
• 230000036280 sedation Effects 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 3
• -1 alphadalone Chemical compound 0.000 description 3
• 201000010099 disease Diseases 0.000 description 3
• 208000024714 major depressive disease Diseases 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 2
• 208000020401 Depressive disease Diseases 0.000 description 2
• PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 description 2
• 206010042458 Suicidal ideation Diseases 0.000 description 2
• 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
• 229960004853 betadex Drugs 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 208000024732 dysthymic disease Diseases 0.000 description 2
• 230000000694 effects Effects 0.000 description 2
• 229950007402 eltanolone Drugs 0.000 description 2
• 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
• 229950006567 ganaxolone Drugs 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• 230000000955 neuroendocrine Effects 0.000 description 2
• 208000015706 neuroendocrine disease Diseases 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 238000004393 prognosis Methods 0.000 description 2
• 238000002603 single-photon emission computed tomography Methods 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• 208000020925 Bipolar disease Diseases 0.000 description 1
• 241000252505 Characidae Species 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 206010010144 Completed suicide Diseases 0.000 description 1
• 239000001116 FEMA 4028 Substances 0.000 description 1
• 208000011688 Generalised anxiety disease Diseases 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 206010065604 Suicidal behaviour Diseases 0.000 description 1
• 229960003305 alfaxalone Drugs 0.000 description 1
• 208000025748 atypical depressive disease Diseases 0.000 description 1
• 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 230000008451 emotion Effects 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 208000029364 generalized anxiety disease Diseases 0.000 description 1
• 239000003163 gonadal steroid hormone Substances 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 201000003995 melancholia Diseases 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 230000007383 nerve stimulation Effects 0.000 description 1
• 230000032696 parturition Effects 0.000 description 1
• 208000028173 post-traumatic stress disease Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000001932 seasonal effect Effects 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1